With 136 chapters spread across 8 sections, the text offers a thorough grounding in issues ranging from medicines regulation to clinical trial design and data management. This makes it a useful revision aid for exams as well as giving you a taster of areas of pharmaceutical medicine adjacent to your current role. For healthcare professionals already working in the field, this book offers a guiding hand in difficult situations as well as supplying rapid access to the latest recommendations and
Written by authors with experience in the industry and drug regulation, this comprehensive and authoritative guide provides a shoulder to lean on throughout your pharmaceutical career.
- Paperback | 480 pages
- 101 x 181 x 18mm | 365g
- 12 Jul 2013
- Oxford University Press
- Oxford, United Kingdom
- 30 black and white images
Other books in this series
28 Feb 2010
Table of contents
About Adrian Kilcoyne
Senior Clinical Research Physician in Diabetes at Eli Lilly. He has since held Medical Director positions at Baxter Healthcare and Roche and is now Medical Director at Sanofi Pasteur MSD, a dedicated vaccine company. Adrian has completed the Diploma in Pharmaceutical Medicine and is a Member of the
Faculty of Pharmaceutical Medicine and has completed Higher medical Training in Pharmaceutical medicine.
Dr. Daniel O'Connor is a Leicester medical graduate with a background in cancer research, histopathology and oncology. He joined the Medicines and Healthcare products Regulatory Agency (MHRA) as a Medical Assessor in 2006 from a clinical lecturer post at UCL/UCH/Ludwig Institute for Cancer Research. He works in the licensing division of the MHRA, mainly reviewing oncology products and is also the UK representative on the Committee for Orphan Medicinal Products (COMP). He completed specialist
training in Pharmaceutical Medicine in 2012. He is a fellow of the Foulkes Foundation.
Dr. Phil Ambery qualified in medicine from the University of Bristol in 1994. He undertook registrar training in the South-West of England and in Sydney, before returning to the UK in 2000 to study diabetes and endocrinology before leaving the NHS to work for GlaxoSmithKline. Since then he has held various posts in the GSK commercial organisation and latterly as a clinical program leader in the metabolic and cardiovascular pathways group at Glaxo. He is also an honorary clinical fellow at
Addenbrooke's Hospital Cambridge, and a GMC specialist partner. He has a number of publications in the field of diabetes and cardiovascular medicine, and on the MRCP examination.